Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

AFT Pharmaceuticals completes first deal in South America

Market and Media release 20 June 2019


AFT Pharmaceuticals’ completes first deal in South America
AFT signs Maxigesic® Licensing Agreement with Barcelona-based Galenicum Vitae S.L.U for Colombia, Peru and Chile.


AFT Pharmaceuticals today announces it has established a beachhead in South America after signing a licensing agreement with Galenicum Vitae.

Galenicum is a Barcelona-based pharmaceutical company with offices across South America and around the globe. It plans to market, sell and distribute AFT’s patented combination analgesic, Maxigesic®, in Colombia, Peru and Chile. Products covered by the new agreement include tablets and oral liquid for paediatric use.

AFT Managing Director, Dr Hartley Atkinson, says: “We are pleased to be making progress on licensing agreements in Latin America. These agreements will be a welcome addition to the Central American markets already licensed, with sales now underway - or due to start – in the current financial year in El Salvador, Guatemala, Honduras, Costa Rica and Nicaragua.”

Dr Atkinson said AFT expects registration approvals in the territories covered by the Galenicum agreement to occur prior to the end of 2021 with sales occurring in the following year.

Galenicum Vitae’s CEO, Sergio Malagrida, said: “For us, including a product such us Maxigesic® in our portfolio represents a great opportunity to provide an innovative product reinforcing our market offering. We believe that this will be the initial launch of a future greater line of products”.

Peru, Colombia and Chile have a combined population of almost 100 million people and the combined retail current value of the over-the-counter pain relief market is NZ$749 million [Euromonitor, 2018.].

Maxigesic® is a patented, fixed ratio of ibuprofen for anti-inflammation management and paracetamol (also called acetaminophen) for pain management.


© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Maritime Union: Deepening Supply Chain Crisis Requires Action

Maritime Union of New Zealand National Secretary Craig Harrison says the global COVID-19 pandemic exposed pre-existing weaknesses in our logistics sector, and created enormous problems... More>>



Air New Zealand: Employees Recognised With $1,000 Share Award

The efforts Air New Zealand employees made during one of the airline’s toughest years will be recognised via an award of $1,000 worth of company shares to all permanent employees... More>>

Consumer NZ: Bank Complaints On The Rise, Survey Shows

Nearly one in five Kiwis had a problem with their bank in the past year, Consumer NZ’s latest satisfaction survey finds. Consumer NZ chief executive Jon Duffy said the number of bank customers reporting problems had jumped to 18%, up from 11% in 2020... More>>

Mercury: Enters Into Binding Agreements To Acquire Trustpower’s Retail Business

Mercury NZ Limited (Mercury) has announced that it has entered into binding agreements with Trustpower Limited (Trustpower, NZX:TPW) to acquire Trustpower’s retail business for NZ$441 million... More>>

ALSO:


ASB: New Zealanders Missing Out On Hundreds Of Millions In KiwiSaver Government Contributions

New Zealanders have just over a week to ensure they’re eligible for the maximum annual government KiwiSaver contribution... More>>


Stats NZ: GDP Climbs 1.6 Percent In March 2021 Quarter Following December Dip

Gross domestic product (GDP) rose by 1.6 percent in the March 2021 quarter, following a 1.0 percent fall in the December 2020 quarter, Stats NZ said today. "After an easing of economic activity in the December quarter, we’ve seen broad-based growth in the first quarter of 2021... More>>